Profluent Bio

Uses transformer-based language models trained on genomic data to computationally design optimal CRISPR guide RNA sequences for specific target genes. The system predicts on-target efficiency and ranks candidate guide RNAs by predicted editing effectiveness.

Predicts potential off-target binding sites and editing events for CRISPR guide RNAs across the genome using AI models. Identifies unintended genomic locations where the guide RNA might cause unwanted edits, enabling researchers to avoid problematic sequences.

Automatically filters and ranks large pools of candidate guide RNAs based on predicted performance metrics, reducing the number of sequences researchers need to experimentally validate. Prioritizes candidates most likely to succeed in wet-lab experiments.

Analyzes genomic sequences using transformer-based language models to extract features relevant to CRISPR editing outcomes. Identifies sequence characteristics that correlate with editing efficiency and specificity.

Optimizes CRISPR guide RNA selection specifically for therapeutic gene editing applications by balancing on-target efficiency, off-target risk, and other clinical safety considerations. Recommends guide RNAs most suitable for therapeutic use.

Streamlines the entire CRISPR experimental design workflow by computationally pre-validating guide RNA candidates before wet-lab work begins. Reduces iteration cycles and failed experiments by prioritizing high-confidence candidates.